Background
Cancer remains a leading cause of death worldwide, and early detection is indispensable for successful treatment and improved patient survival rates. However, many existing cancer diagnostic methods, particularly invasive procedures like tissue biopsies, pose a significant burden on patients and often lack sensitivity in early stages. In recent years, “liquid biopsy,” which involves detecting cancer-related biomarkers from body fluid samples such as blood, urine, and saliva, has gained attention as a promising new diagnostic approach enabling non-invasive and continuous monitoring. In this context, electrochemical biosensors are emerging as a promising technology for cancer biomarker detection due to their high sensitivity, selectivity, and speed.
Key Findings / Results
This review article illustrates how electrochemical biosensors are powerful tools for detecting cancer biomarkers, exploring their journey from molecular-level sensing to clinical translation. The primary focus areas include:
- Electrochemical Detection of Diverse Biomarkers:
- Protein Biomarkers: Details how electrochemical sensors are applied to detect protein markers associated with specific cancer types, such as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and C-reactive protein (CRP). Changes in the concentration of these markers serve as indicators of cancer presence or progression.
- Nucleic Acid Markers: Nucleic acid molecules released from cancer cells, such as circulating tumor DNA (ctDNA) and microRNA (miRNA), are highly promising targets for non-invasive diagnosis. Research is advancing on electrochemical sensors for the high-sensitivity detection of these trace nucleic acids without the need for PCR.
- Metabolic Indicators: Detection of molecules related to cancer cell-specific metabolic changes (e.g., lactate, glucose, specific metabolites) is also being utilized for diagnosis and monitoring of treatment efficacy.
- Nanomaterial-Based Enhancements: Nanomaterials like gold nanoparticles, graphene, carbon nanotubes, and quantum dots dramatically enhance the sensitivity and detection limits of electrochemical biosensors by increasing the effective surface area of electrodes, improving electron transfer rates, and providing signal amplification. They also offer an ideal platform for immobilizing biorecognition elements (e.g., antibodies, aptamers).
- Rapid Response and Cost-Effectiveness: Electrochemical detection often does not require complex optical instruments or expensive reagents, providing rapid results. This significantly reduces time and cost compared to traditional lab-based assays.
Challenges and Prospects for Clinical Translation
For electrochemical biosensors to be widely adopted in clinical settings, several challenges must be overcome. These include reducing interference from complex biological samples, ensuring long-term stability, establishing standardized manufacturing processes, and conducting large-scale clinical validations. However, due to their advantages—rapid response, high sensitivity, analytical specificity, and cost-effective operation—these devices enable quick and portable measurements from “liquid biopsy” samples, with promising clinical applications such as:
- Early Cancer Screening: Used as part of routine health check-ups, enabling ultra-early detection before symptoms appear.
- Monitoring Treatment Efficacy: Continuously tracks biomarker levels during treatment to assess its effectiveness in real-time.
- Recurrence Surveillance: Detects early signs of recurrence during regular follow-ups for post-cancer treatment patients.
- Personalized Medicine: Provides information to select optimal treatment strategies based on each patient’s unique biomarker profile.
These advancements will play a crucial role in shaping the future of cancer diagnostics, improving patient outcomes, and enhancing the efficiency of healthcare systems.
Comments